Sunho Biologics Suspends Trading Pending 2025 Annual Results

Bulletin Express
04/01

Sunho Biologics, Inc. announced that trading in its shares on the Stock Exchange of Hong Kong has been halted at the company’s request from 9:00 a.m. on 1 April 2026.

The suspension follows earlier notices dated 27 March 2026 and 30 March 2026, which disclosed a delay in publishing the firm’s audited 2025 annual results and the postponement of the corresponding board meeting.

Trading will remain suspended until Sunho Biologics releases the outstanding 2025 annual results announcement.

As of the suspension date, the board comprises Executive Directors Mr. Zhang Feng (Chairman) and Ms. Jiang Xiaoling; Non-Executive Director Mr. Fan Rongkui; and Independent Non-Executive Directors Mr. Chan Heung Wing Anthony, Ms. Feng Lan and Mr. Shi Luwen.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10